ERBB2 and neoplasm: It is plausible that further optimization of doses and dosing schedules for the two triple combination strategies may eventually be able to result in significant difference between the two groups, considering that pyrotinib is a pan-HER inhibitor, that simultaneously blocks the signaling of three HER family members, whereas pertuzumab specifically binds and inhibits only HER2, and that the combination of inetetamab with pyrotinib resulted in stronger inhibition of JIMT-1 tumor growth than the combination of trastuzumab with pertuzumab (Figure 1a).